U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H22N6O3
Molecular Weight 418.4485
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FUTIBATINIB

SMILES

COC1=CC(=CC(OC)=C1)C#CC2=NN([C@H]3CCN(C3)C(=O)C=C)C4=C2C(N)=NC=N4

InChI

InChIKey=KEIPNCCJPRMIAX-HNNXBMFYSA-N
InChI=1S/C22H22N6O3/c1-4-19(29)27-8-7-15(12-27)28-22-20(21(23)24-13-25-22)18(26-28)6-5-14-9-16(30-2)11-17(10-14)31-3/h4,9-11,13,15H,1,7-8,12H2,2-3H3,(H2,23,24,25)/t15-/m0/s1

HIDE SMILES / InChI
Molecular Formula C22H22N6O3
Molecular Weight 418.4485
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Futibatinib (Lytgobi®) is an oral, covalently binding, irreversible inhibitor of fibroblast growth factor receptor (FGFR)1-4 that is being developed by Taiho Oncology and Taiho Pharmaceutical for the treatment of cancers, including cholangiocarcinoma, breast cancer, gastric cancer, urothelial cancer, oesophageal cancer and non-small cell lung cancer. Futibatinib is a small molecule kinase inhibitor of FGFR 1, 2, 3, and 4 with IC50 values of less than 4 nM. Futibatinib covalently binds FGFR. Constitutive FGFR signaling can support the proliferation and survival of malignant cells. Futibatinib inhibited FGFR phosphorylation and downstream signaling and decreased cell viability in cancer cell lines with FGFR alterations including FGFR fusions/rearrangements, amplifications, and mutations. Futibatinib demonstrated anti-tumor activity in mouse and rat xenograft models of human tumors with activating FGFR genetic alterations. Futibatinib was approved in the USA on 30 September 2022 for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harbouring FGFR2 gene fusions or other rearrangements.

Approval Year

2022
324
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
 3.9 nM [IC50]
Inhibitor
8504
 1.3 nM [IC50]
Inhibitor
8504
 1.6 nM [IC50]
Inhibitor
8504
 8.3 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
LYTGOBI

Approved Use

LYTGOBI is a kinase inhibitor indicated for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.

Launch Date

2022
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
96.2 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/36382853/
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FUTIBATINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
163.6 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/36382853/
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FUTIBATINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
144 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf
20 mg 1 times / day steady-state, oral
dose: 20 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
FUTIBATINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
592.9 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/36382853/
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FUTIBATINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
673.8 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/36382853/
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FUTIBATINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
790 ng × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf
20 mg 1 times / day steady-state, oral
dose: 20 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
FUTIBATINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.5 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/36382853/
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FUTIBATINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
2.6 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/36382853/
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FUTIBATINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
2.9 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf
20 mg 1 times / day steady-state, oral
dose: 20 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
FUTIBATINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
5%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf
20 mg 1 times / day steady-state, oral
dose: 20 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
FUTIBATINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
20 mg 1 times / day steady, oral
MTD|Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214801Orig1s000MultidisciplineR.pdf
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214801Orig1s000MultidisciplineR.pdf
Disc. AE: Anemia, Gastrointestinal disorders...
AEs leading to
discontinuation/dose reduction:
Anemia (1 patient)
Gastrointestinal disorders (2 patients)
Hepatobilliary disorders (1 patient)
Hypoglycemia (1 patient)
Neoplasms benign, malignant and unspecified (2 patients)
Dizziness (1 patient)
Pharyngeal inflammation (1 patient)
Gastrointestinal disorders (4 patients)
Fatigue (5 patients)
Alanine aminotransferase increased (5 patients)
Aspartate aminotransferase increased (4 patients)
Blood creatine phosphokinase increased (2 patients)
Metabolism and nutrition disorders (21 patient)
Nervous system disorders (4 patients)
Skin and subcutaneous tissue disorders (17 patients)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214801Orig1s000MultidisciplineR.pdf
AEs

AEs

AESignificanceDosePopulation
Anemia 1 patient
Disc. AE
20 mg 1 times / day steady, oral
MTD|Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214801Orig1s000MultidisciplineR.pdf
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214801Orig1s000MultidisciplineR.pdf
Dizziness 1 patient
Disc. AE
20 mg 1 times / day steady, oral
MTD|Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214801Orig1s000MultidisciplineR.pdf
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214801Orig1s000MultidisciplineR.pdf
Hepatobilliary disorders 1 patient
Disc. AE
20 mg 1 times / day steady, oral
MTD|Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214801Orig1s000MultidisciplineR.pdf
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214801Orig1s000MultidisciplineR.pdf
Hypoglycemia 1 patient
Disc. AE
20 mg 1 times / day steady, oral
MTD|Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214801Orig1s000MultidisciplineR.pdf
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214801Orig1s000MultidisciplineR.pdf
Pharyngeal inflammation 1 patient
Disc. AE
20 mg 1 times / day steady, oral
MTD|Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214801Orig1s000MultidisciplineR.pdf
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214801Orig1s000MultidisciplineR.pdf
Skin and subcutaneous tissue disorders 17 patients
Disc. AE
20 mg 1 times / day steady, oral
MTD|Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214801Orig1s000MultidisciplineR.pdf
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214801Orig1s000MultidisciplineR.pdf
Blood creatine phosphokinase increased 2 patients
Disc. AE
20 mg 1 times / day steady, oral
MTD|Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214801Orig1s000MultidisciplineR.pdf
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214801Orig1s000MultidisciplineR.pdf
Gastrointestinal disorders 2 patients
Disc. AE
20 mg 1 times / day steady, oral
MTD|Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214801Orig1s000MultidisciplineR.pdf
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214801Orig1s000MultidisciplineR.pdf
Neoplasms benign, malignant and unspecified 2 patients
Disc. AE
20 mg 1 times / day steady, oral
MTD|Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214801Orig1s000MultidisciplineR.pdf
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214801Orig1s000MultidisciplineR.pdf
Metabolism and nutrition disorders 21 patient
Disc. AE
20 mg 1 times / day steady, oral
MTD|Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214801Orig1s000MultidisciplineR.pdf
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214801Orig1s000MultidisciplineR.pdf
Aspartate aminotransferase increased 4 patients
Disc. AE
20 mg 1 times / day steady, oral
MTD|Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214801Orig1s000MultidisciplineR.pdf
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214801Orig1s000MultidisciplineR.pdf
Gastrointestinal disorders 4 patients
Disc. AE
20 mg 1 times / day steady, oral
MTD|Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214801Orig1s000MultidisciplineR.pdf
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214801Orig1s000MultidisciplineR.pdf
Nervous system disorders 4 patients
Disc. AE
20 mg 1 times / day steady, oral
MTD|Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214801Orig1s000MultidisciplineR.pdf
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214801Orig1s000MultidisciplineR.pdf
Alanine aminotransferase increased 5 patients
Disc. AE
20 mg 1 times / day steady, oral
MTD|Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214801Orig1s000MultidisciplineR.pdf
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214801Orig1s000MultidisciplineR.pdf
Fatigue 5 patients
Disc. AE
20 mg 1 times / day steady, oral
MTD|Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214801Orig1s000MultidisciplineR.pdf
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214801Orig1s000MultidisciplineR.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
2438

substrate
1193
inhibitor
2507

substrate
1388
inhibitor
2217

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP2C8
1057

CYP3A
227

MATE1
415

P-gp
1741

BCRP
910

CYP1A2
2153

CYP2B6
926

MATE2K
17

CYP2C19
2057

OATP1B1
1079

OATP1B3
961

OAT1
725

OAT3
747

OCT2
779
P-gp
2052

CYP3A
220

BCRP
697

OATP1B3
435

OATP1B1
503
CYP2B6
669

CYP1A2
832

CYP3A
142
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
OAT1
730
 no [IC50 >60 uM]
OAT3
749
 no [IC50 >60 uM]
CYP1A2
2333
 no
CYP2B6
1160
 no
CYP2B6
1160
 no
CYP2D6
2546
 no
CYP3A
317
 no
OCT2
782
 no
CYP3A
317
 no
no (co-administration study)
Comment: Multiple doses of futibatinib (20mg QD x 7) increased midazolam Cmax by 5% and AUC by 8%.
Page: 47 | 184
CYP1A2
2333
 weak
P-gp
1932
 yes [IC50 0.296 uM]
BCRP
985
 yes [IC50 0.348 uM]
OATP1B3
970
 yes [IC50 16.418 uM]
OATP1B1
1095
 yes [IC50 2.845 uM]
CYP2C19
2141
 yes
CYP2C8
1117
 yes
CYP2C9
2497
 yes
MATE1
416
 yes
MATE2K
17
 yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP3A
220
 major
yes (co-administration study)
Comment: Itraconazole (20mg SD) increased Cmax by 51% and AUC by 41% following 20 mg SD futibatinib
Page: 47 | 70 | 83 | 181
CYP2C9
1193
 minor
CYP2D6
1388
 minor
OATP1B1
503
 no
OATP1B3
435
 no
BCRP
697
 yes
P-gp
2052
 yes
yes (co-administration study)
Comment: Rifampicin (strong CYP3A/P-gp inducer, 600mg QD) decreased futibatinib (20mg SD) Cmax by 53% and AUC by 64%
Page: 47 | 83 | 181
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
2263
PubMed

PubMed

TitleDatePubMed
Patents

Patents

US-2014343035-A1
1
US-9108973-B2
1
WO2013108809
1

Sample Use Guides

In Vivo Use Guide
Recommended dose is 20 mg orally (five 4 mg tablets) once daily until disease progression or unacceptable toxicity occurs.
Route of Administration: Oral
In Vitro Use Guide
Among a panel of 296 human kinases, futibatinib selectively inhibited FGFR1-4 with IC50 values of 1.4 to 3.7 nmol/L.
Substance Class Chemical
Created
by admin
on Mon Mar 31 22:31:04 GMT 2025
Edited
by admin
on Mon Mar 31 22:31:04 GMT 2025
Record UNII
4B93MGE4AL
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LYTGOBI
Preferred Name English
FUTIBATINIB
USAN   INN  
Official Name English
Futibatinib [WHO-DD]
Common Name English
FUTIBATINIB [USAN]
Common Name English
futibatinib [INN]
Common Name English
FGFR-IN-1
Common Name English
TAS-120
Code English
FUTIBATINIB [JAN]
Common Name English
2-PROPEN-1-ONE, 1-((3S)-3-(4-AMINO-3-(2-(3,5-DIMETHOXYPHENYL)ETHYNYL)-1H-PYRAZOLO(3,4-D)PYRIMIDIN-1-YL)-1-PYRROLIDINYL)-
Systematic Name English
Classification Tree Code System Code
EU-Orphan Drug EU/3/19/2146
Created by admin on Mon Mar 31 22:31:04 GMT 2025 , Edited by admin on Mon Mar 31 22:31:04 GMT 2025
FDA ORPHAN DRUG 635018
Created by admin on Mon Mar 31 22:31:04 GMT 2025 , Edited by admin on Mon Mar 31 22:31:04 GMT 2025
Code System Code Type Description
CAS
1814961-20-0
Created by admin on Mon Mar 31 22:31:04 GMT 2025 , Edited by admin on Mon Mar 31 22:31:04 GMT 2025
NO STRUCTURE GIVEN
FDA UNII
4B93MGE4AL
Created by admin on Mon Mar 31 22:31:04 GMT 2025 , Edited by admin on Mon Mar 31 22:31:04 GMT 2025
PRIMARY
SMS_ID
100000180711
Created by admin on Mon Mar 31 22:31:04 GMT 2025 , Edited by admin on Mon Mar 31 22:31:04 GMT 2025
PRIMARY
DAILYMED
4B93MGE4AL
Created by admin on Mon Mar 31 22:31:04 GMT 2025 , Edited by admin on Mon Mar 31 22:31:04 GMT 2025
PRIMARY
USAN
GH-182
Created by admin on Mon Mar 31 22:31:04 GMT 2025 , Edited by admin on Mon Mar 31 22:31:04 GMT 2025
PRIMARY
INN
10879
Created by admin on Mon Mar 31 22:31:04 GMT 2025 , Edited by admin on Mon Mar 31 22:31:04 GMT 2025
PRIMARY
NCI_THESAURUS
C114283
Created by admin on Mon Mar 31 22:31:04 GMT 2025 , Edited by admin on Mon Mar 31 22:31:04 GMT 2025
PRIMARY
DRUG BANK
DB15149
Created by admin on Mon Mar 31 22:31:04 GMT 2025 , Edited by admin on Mon Mar 31 22:31:04 GMT 2025
PRIMARY
CAS
1448169-71-8
Created by admin on Mon Mar 31 22:31:04 GMT 2025 , Edited by admin on Mon Mar 31 22:31:04 GMT 2025
PRIMARY
PUBCHEM
71621331
Created by admin on Mon Mar 31 22:31:04 GMT 2025 , Edited by admin on Mon Mar 31 22:31:04 GMT 2025
PRIMARY
Related Record Type Details
FIBROBLAST GROWTH FACTOR RECEPTOR 2
TARGET -> INHIBITOR
FIBROBLAST GROWTH FACTOR RECEPTOR 3
TARGET -> INHIBITOR
FIBROBLAST GROWTH FACTOR RECEPTOR 4
TARGET -> INHIBITOR
FIBROBLAST GROWTH FACTOR RECEPTOR 1
TARGET -> INHIBITOR
Related Record Type Details
Structure of FUTIBATINIB
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966